Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
27 participants
INTERVENTIONAL
2011-10-31
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral medical nutritional supplement without AN777
orally over a three hour period
Oral medical nutritional supplement
orally over a three hour period
Experimental oral medical nutritional supplement with AN777
orally over a three hour period
Experimental oral medical nutritional supplement with AN777
orally over a three hour period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral medical nutritional supplement
orally over a three hour period
Experimental oral medical nutritional supplement with AN777
orally over a three hour period
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) \> 20.0, but \< 35.0.
* Ability to climb a flight of 10 stairs or walk an equivalent of city block without help within the 3 months prior to enrollment.
* Refrain from taking any dose of NSAIDs or acetaminophen on the day of and 24 hours prior to Visit 2 and Visit 3.
* Refrain from using any pulmonary maintenance medications on the days of Visit 2 and Visit
* Refrain from intense physical activity between visits.
Exclusion Criteria
* Blood thinner or anticoagulant medication within 1 week prior to enrollment.
* Glomerular filtration rate (eGFR) of \< 40 mL/min/1.73m2.
* Antibiotics within 1 week prior to enrollment.
* Major surgery less than 3 months prior to enrollment in the study.
* Active malignant disease or treated within the last 6 months for cancer.
* Immunodeficiency disorder.
* Diabetes
* Myocardial infarction 3 months prior to enrollment.
* Chronic obstructive pulmonary disease
* History of allergy to any of the ingredients in the study products.
* Conditions precluding ingestion or absorption of the study product, inflammatory bowel disease, short bowel syndrome, or other major gastrointestinal disease.
* Dementia, brain metastases, eating disorders, history of significant neurological or psychiatric disorder, or any other psychological condition.
* Pursuing weight loss or weight gain.
* Medications/dietary supplements/substances that could modulate metabolism or weight.
60 Years
90 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Nutrition
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vikkie Mustad, PhD
Role: STUDY_CHAIR
Abbott Nutrition
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BK96
Identifier Type: -
Identifier Source: org_study_id